Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesLeMaitre Vascular Inc

LeMaitre Vascular Inc

Healthcare Medical Instruments & Supplies
PortfolioPortfolio WatchlistWatchlist
Company price
80.225 USD -0.94 ( 1.15%)
Last update at 2026-11-10T15:09:00Z
VOLUME
9886
Market Cap
1835.03M
P/E
28.25

Momentum Score

…

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
80.22
Low
80.73
High
52 Week Price Range
78.27
Low
117.37
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

LeMaitre Vascular manufactures and distributes surgical devices and implants used to treat peripheral and vascular disease for hospitals and vascular specialists in domestic and international markets. Long-term growth may be supported by aging populations, rising vascular disease prevalence, product development and greater adoption of minimally invasive approaches, which could appeal to investors seeking a focused vascular med‑tech franchise.
Key risks include sensitivity to procedure volumes and reimbursement, competition from larger device makers, regulatory uncertainty and execution and supply‑chain risks typical of smaller manufacturers.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
81.16
Dividend Yield
1.11%
Revenue TTM
262.43M
Revenue Per Share
11.53
Gross Profit TTM
188.60M
Debt / Equity
0.47
ROE
16.77%
Net Debt
157.35M
ROCE
13.87%
Diluted EPS TTM
2.84

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 75.18M 56.88M 39.48M 27.49M 34.29M
Net income 57.73M 44.04M 30.11M 20.64M 26.91M
Selling general administrative 42.02M 36.26M 31.83M 28.75M 25.50M
Selling and marketing expenses 54.46M 46.74M 41.05M 32.92M 27.66M
Gross profit 178.54M 150.90M 127.05M 104.90M 101.38M
Reconciled depreciation 10.42M 9.67M 9.36M 9.43M 11.07M
Ebit 80.37M 57.08M 39.48M 21.16M 25.55M
Ebitda 90.79M 66.75M 48.99M 30.60M 36.62M
Depreciation and amortization 10.42M 9.67M 9.52M 9.43M 11.07M
Non operating income net other - - - 0.66M 0.08M
Operating income 67.91M 52.26M 36.71M 21.16M 25.55M
Other operating expenses 181.69M 167.61M 156.77M 131.72M 118.00M
Interest expense 5.18M 0.20M 0.00M 0.99M 2.22M
Tax provision 17.45M 12.84M 8.69M 6.85M 7.38M
Interest income - 4.95M 2.53M 0.99M 0.20M
Net interest income -5.18M 4.74M 2.53M 0.99M -2.02M
Non recurring - - - 3.11M -
Income tax expense 17.45M 12.84M 9.37M 6.85M 7.38M
Total revenue 249.60M 219.86M 193.48M 161.65M 154.42M
Total operating expenses 110.63M 98.64M 90.34M 74.96M 64.96M
Cost of revenue 71.06M 68.96M 66.44M 56.76M 53.04M
Total other income expense net 7.27M 4.62M 2.76M 6.33M 8.73M
Net income from continuing ops 57.73M 44.04M 27.27M 20.64M 26.91M
Net income applicable to common shares - - - 20.64M 26.91M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 615.69M 551.82M 346.78M 310.48M 292.80M
Intangible assets 33.09M 35.82M 41.71M 46.53M 52.71M
Other current assets 5.08M 16.46M 6.38M 6.73M 4.19M
Total liab 222.17M 214.53M 48.88M 42.27M 38.65M
Total stockholder equity 393.52M 337.29M 297.90M 268.20M 254.15M
Deferred long term liab - - - - 0.07M
Other current liab 29.73M 10.41M 23.28M 20.54M 1.27M
Common stock 0.24M 0.24M 0.24M 0.24M 0.23M
Capital stock 0.24M 0.24M 0.24M 0.24M 0.23M
Retained earnings 184.72M 145.09M 115.43M 97.77M 88.12M
Other liab - - - 2.24M 2.77M
Good will 65.94M 65.94M 65.94M 65.94M 65.94M
Other assets - - - 2.74M 2.13M
Cash 28.24M 25.61M 24.27M 19.13M 13.86M
Total current liabilities 36.32M 30.61M 29.88M 25.33M 21.81M
Current deferred revenue - - 0.39M - 16.33M
Net debt 157.35M 160.07M -5.17M -2.54M 2.08M
Short term debt 2.94M 2.68M 2.47M 1.89M 1.87M
Short long term debt total 185.59M 185.69M 19.09M 16.60M 15.94M
Other stockholder equity 210.97M 198.14M 186.86M 176.22M 169.23M
Property plant equipment - - - 17.90M 32.13M
Total current assets 468.23M 402.19M 188.85M 161.73M 139.88M
Net tangible assets - - - 155.73M 135.50M
Short term investments 330.88M 274.11M 80.81M 63.56M 56.10M
Net receivables 33.61M 30.06M 25.06M 22.04M 19.63M
Long term debt 168.65M 167.77M - - -
Inventory 70.42M 55.94M 52.33M 50.27M 46.10M
Accounts payable 3.65M 1.76M 3.73M 2.90M 2.34M
Accumulated other comprehensive income -2.41M -6.18M -4.62M -6.03M -3.44M
Common stock total equity - - - 0.24M 0.23M
Retained earnings total equity - - - 97.77M 88.12M
Treasury stock - - - -13.05M -12.40M
Non currrent assets other 4.91M 4.87M 9.49M 0.99M 0.57M
Non current assets total 147.46M 149.62M 157.93M 148.74M 152.92M
Capital lease obligations 16.95M 17.91M 19.09M 16.60M 15.94M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -56.26M -200.12M -22.86M -8.00M -56.19M
Change to liabilities - - - 0.65M -1.73M
Total cashflows from investing activities -64.94M -200.12M - -10.37M -61.08M
Net borrowings 0.00M 169.27M - - -39.00M
Total cash from financing activities -14.54M 158.10M -7.13M -9.23M 13.70M
Change to operating activities - - - -3.10M -1.93M
Net income 57.73M 44.04M 30.11M 20.64M 26.91M
Change in cash 2.63M 1.34M 5.13M 5.28M -12.91M
Begin period cash flow 25.61M 24.27M 19.13M 13.86M 26.76M
End period cash flow 28.24M 25.61M 24.27M 19.13M 13.86M
Total cash from operating activities 81.25M 44.12M 36.75M 25.38M 35.10M
Issuance of capital stock - 6.44M 6.86M 3.47M 63.24M
Depreciation 10.42M 9.67M 9.52M 9.43M 11.07M
Other cashflows from investing activities - - - 0.86M -
Dividends paid 18.11M 14.38M 12.45M 10.99M 9.34M
Change to inventory -7.22M -10.57M -9.79M -7.42M -5.49M
Change to account receivables -2.95M -6.42M -3.13M -3.53M -0.82M
Sale purchase of stock - -1.72M -0.85M -0.64M -0.80M
Other cashflows from financing activities -3.25M -3.23M 7.13M -1.07M -0.40M
Change to netincome - - - 8.71M 7.09M
Capital expenditures 6.78M 6.96M 7.26M 3.23M 4.88M
Change receivables - - - -3.53M -0.82M
Cash flows other operating - - - -10.51M -7.41M
Cash and cash equivalents changes - - - 5.77M -12.27M
Change in working capital -1.75M -20.10M -11.25M -13.40M -9.96M
Stock based compensation 7.83M 6.57M 5.32M 4.17M 3.48M
Other non cash items 4.71M 4.40M 2.28M 4.72M 3.53M
Free cash flow 74.47M 37.16M 29.49M 22.15M 30.22M

Peer Comparison*

Sector: Healthcare Industry: Medical Instruments & Supplies

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
LMAT
LeMaitre Vascular Inc		 -0.94
1.15%		 80.22 28.25 25.71 6.99 4.40 6.34 16.57
ISRG
Intuitive Surgical Inc		 -7.32
1.59%		 453.24 43.30 31.35 12.25 7.35 11.63 30.22
ESLOF
EssilorLuxottica Société anonyme		 0.23
0.11%		 213.23 44.84 27.62 4.07 2.49 3.71 16.04
ESLOY
Essilor International SA		 -2.57
2.40%		 104.63 41.68 27.25 3.94 2.45 3.71 16.04
BDX
Becton Dickinson and Company		 -3.20
1.49%		 212.05 31.62 13.76 2.25 2.04 2.93 13.40

Profile*

LeMaitre Vascular Inc

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

63 Second Avenue, Burlington, MA, United States, 01803

781 221 2266

https://www.lemaitre.com

646

Name Title Year Born
Mr. George W. LeMaitre Chairman & CEO 1965
Mr. David B. Roberts Pres & Director 1964
Mr. Joseph P. Pellegrino Jr. CFO, Treasurer, Sec. & Director 1965
Mr. Trent G. Kamke Sr. VP of Operations 1971
Dr. George D. LeMaitre Founder and Chairman of Scientific Advisory Board 1934
Ms. Laurie A. Churchill Sr. VP & Gen. Counsel 1971
Ms. Kimberly L. Cieslak VP of Marketing 1973
Mr. Daniel J. Mumford Director of HR 1982
Mr. Andrew Hodgkinson Sr. VP of Clinical, Regulatory & Quality Affairs 1976
Mr. Stephane Maier Sr. VP of EMEA Operations 1976

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

QTWO
CAD 1.78
+10.56%
NEO
CAD 27.77
+5.91%
CGI
CAD 52.81
+4.78%
PET
CAD 22.34
+3.81%
QBR-A
CAD 77.96
+2.40%
GFL
CAD 57.98
-10.54%
MUX
CAD 21.12
-7.53%
BYN
CAD 1.58
-7.06%
BRVO
CAD 2.23
-6.89%
ITR
CAD 3.12
-6.87%

Equity Sectors*

  • Basic Materials

    -4.26%

  • Communication Services

    +0.36%

  • Consumer Cyclical

    -0.62%

  • Consumer Defensive

    -0.33%

  • Energy

    -0.09%

  • Financial Services

    -0.18%

  • Healthcare

    -1.69%

  • Industrials

    -1.10%

  • Real Estate

    -0.83%

  • Technology

    -0.67%

  • Utilities

    +0.31%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…